---
title: "Brainstorm Cell Therapeutics Arranges Up to $1.0 Million Private Placement at $0.60, Adds Warrants"
description: "Brainstorm Cell Therapeutics has arranged a private placement of up to $1.0 million with an accredited investor, offering common stock at $0.60 per share and pre-funded warrants at $0.5995. The deal i"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277251891.md"
published_at: "2026-02-27T21:35:55.000Z"
---

# Brainstorm Cell Therapeutics Arranges Up to $1.0 Million Private Placement at $0.60, Adds Warrants

> Brainstorm Cell Therapeutics has arranged a private placement of up to $1.0 million with an accredited investor, offering common stock at $0.60 per share and pre-funded warrants at $0.5995. The deal includes common warrants with 120% coverage at a $1.00 exercise price. The transaction will close in multiple tranches until September 25, 2026, with the first closing of $125,000 already completed on February 24, 2026. Proceeds will be utilized for working capital.

Brainstorm Cell Therapeutics entered into a Securities Purchase Agreement with an accredited investor for a private placement of up to $1.0 million. The deal includes common stock at $0.60 per share or pre-funded warrants priced at $0.5995 with a $0.00005 exercise price, plus common warrants equal to 120% coverage at a $1.00 exercise price. The transaction may close in up to eight tranches through September 25, 2026; the first $125,000 closing occurred on February 24, 2026. Proceeds will be used for working capital.

**Agreement details:**

-   **Agreement type**: Securities Purchase Agreement for multi-closing private placement of common stock and warrants
-   **Counterparty**: Accredited investor
-   **Signed / Effective**: Feb 24 2026 / same
-   **Duration / Termination**: Through Sep 25 2026
-   **Reason**: Raise working capital

Original SEC Filing: BRAINSTORM CELL THERAPEUTICS INC. \[ BCLI \] - 8-K - Feb. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BCLI.US - Brainstorm Cell](https://longbridge.com/en/quote/BCLI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Brainstorm Cell Therapeutics 公司獲得第二筆 100 萬美元的戰略投資；2 月份總共籌集了 200 萬美元 \| BCLI 股票新聞 | Brainstorm Cell Therapeutics Inc.（OTCQB: BCLI）已獲得第二筆 100 萬美元的戰略私人配售，總計在 2026 年 2 月籌集了 200 萬美元。這筆資金將支持監管和臨牀目標，包括其 NurOwn® | [Link](https://longbridge.com/en/news/277030604.md) |
| Brainstorm Cell Therapeutics 通過未註冊的票據發行籌集資金 | Brainstorm Cell Therapeutics Inc. 已通過三次與機構投資者的未註冊本票發行籌集超過 329,000 美元。這些交易在 2025 年 12 月 31 日至 2026 年 1 月 6 日之間完成，涉及與 Vanq | [Link](https://longbridge.com/en/news/272124552.md) |
| ELF Beauty 的股票是否會漲到 100 美元？ | 該股票很有可能很快達到 100 美元的價格點 | [Link](https://longbridge.com/en/news/277126350.md) |
| 這隻 AI 股票正在跑贏市場，並可能在 2026 年繼續上漲 | 這隻人工智能股票正在超越市場，並可能在 2026 年繼續上漲 | [Link](https://longbridge.com/en/news/276619136.md) |
| Ferguson Enterprises Inc. 提供了2026年1月1日至2026年12月31日期間的盈利指引 | Ferguson Enterprises Inc. 提供了 2026 年 1 月 1 日至 2026 年 12 月 31 日的收益指引。公司預計淨銷售額將實現低至中個位數的增長 | [Link](https://longbridge.com/en/news/276736124.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.